ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

357
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
Refresh
16 Aug 2020 17:17

HSCI Index Rebalance - Stock Connect Flows Coming Up

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....

Logo
472 Views
Share
bullishWuxi Biologics
15 Aug 2020 10:42

Hang Seng Index Rebalance - Big Turnover, Big Impact, Some Surprises and More Changes to Come

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....

Logo
967 Views
Share
22 Jul 2020 19:49

Innovent Biologics (信达生物) Placement - Back on the Market but This Time with Secondary Selldown

Innovent Biologics Inc (1801 HK) is looking to raise about U$290m to fund expansion and concurrently, shareholders are looking to sell about 33.8m...

Share
18 May 2020 15:32

Legend Biotech IPO Initiation: Choosing Therapies À La CAR-T

Legend Biotech (BLG US) is one of the leading companies in developing CAR-T cell therapies in China, having received clearance for the first CAR-T...

Logo
142 Views
Share
11 May 2020 14:25

Short Interest Spiked for China Gas, Country Garden Svc, Big Covers for Innovent

Hong Kong SFC reported today for aggregate short position on Apr 29. The aggregate short value for equities increased by $1,489m (+2.7%) WoW and...

Logo
234 Views
Share
x